GOUT
MCID: GT001
MIFTS: 63

Gout (GOUT)

Categories: Blood diseases, Bone diseases, Metabolic diseases, Nephrological diseases, Skin diseases

Aliases & Classifications for Gout

MalaCards integrated aliases for Gout:

Name: Gout 12 75 25 37 55 6 43 3 44 15 63 17 72 33
Arthritis, Gouty 25 44 72
Gouty Arthritis 12 25 15
Gouty Arthropathy 12 25
Articular Gout 12 25
Arthritis Gouty 55

Classifications:



External Ids:

Disease Ontology 12 DOID:13189
KEGG 37 H01532
NCIt 50 C34650
SNOMED-CT 68 48440001 90560007
UMLS 72 C0003868 C0018099

Summaries for Gout

Genetics Home Reference : 25 Gout is a type of arthritis, which is a group of related disorders caused by episodes of abnormal inflammation in the joints. People with gout have high levels of a substance called urate in the blood (hyperuricemia). Gout develops when hyperuricemia leads to the formation of urate crystals in joints, triggering an inflammatory response from the immune system. In people with gout, the first episode of inflammation (called a flare) usually affects the big toe or other joints in the foot or ankle. If urate levels remain high, flares can recur, affecting additional joints throughout the body. The time between flares varies among affected individuals; however, most people who experience multiple flares have their second one within a year of their first. Flares usually begin at night and can last several days. It is unclear what causes a flare to stop; the body likely turns off the inflammation response after a certain period of time. During a flare, individuals can experience throbbing or burning pain, swelling, warmth, redness, and difficulty moving the affected joint. Fevers may occur, after which the skin over the affected joint can begin to peel. Without treatment, people with gout can experience frequent flares and joint pain and damage, which can limit mobility and decrease quality of life. In about 15 percent of people with gout, urate accumulates in the kidneys and forms kidney stones. As the condition worsens, urate crystals can also be deposited under the skin or in other soft tissue, forming a nodule called a tophus (plural: tophi). These tophi often form in the hands, elbows, or feet. Tophi do not typically cause pain, but they can become inflamed, infected, or ooze fluid. Depending on their location, tophi can interfere with movements such as walking or gripping objects. Many people with gout also have other health conditions. Most affected individuals have high blood pressure (hypertension), chronic kidney disease, or obesity. Some also have diabetes, heart disease, or a history of stroke. It is unclear whether gout is the cause of a person's increased risk for these conditions, or whether the conditions cause the development of gout, or whether both of these situations occur to influence disease.

MalaCards based summary : Gout, also known as arthritis, gouty, is related to phosphoribosylpyrophosphate synthetase superactivity and hyperuricemic nephropathy, familial juvenile, 1, and has symptoms including back pain, sciatica and muscle cramp. An important gene associated with Gout is DARS2 (Aspartyl-TRNA Synthetase 2, Mitochondrial), and among its related pathways/superpathways are Purine metabolism and Thiopurine Pathway, Pharmacokinetics/Pharmacodynamics. The drugs Diclofenac and Lumiracoxib have been mentioned in the context of this disorder. Affiliated tissues include kidney, heart and bone, and related phenotypes are no effect and homeostasis/metabolism

Disease Ontology : 12 An arthritis that has material basis in uric acid crystal deposits located in joint.

MedlinePlus : 43 Gout is a common, painful form of arthritis. It causes swollen, red, hot and stiff joints. Gout happens when uric acid builds up in your body. Uric acid comes from the breakdown of substances called purines. Purines are in your body's tissues and in foods, such as liver, dried beans and peas, and anchovies. Normally, uric acid dissolves in the blood. It passes through the kidneys and out of the body in urine. But sometimes uric acid can build up and form needle-like crystals. When they form in your joints, it is very painful. The crystals can also cause kidney stones. Often, gout first attacks your big toe. It can also attack ankles, heels, knees, wrists, fingers, and elbows. At first, gout attacks usually get better in days. Eventually, attacks last longer and happen more often. You are more likely to get gout if you Are a man Have family member with gout Are overweight Drink alcohol Eat too many foods rich in purines Gout can be hard to diagnose. Your doctor may take a sample of fluid from an inflamed joint to look for crystals. You can treat gout with medicines. Pseudogout has similar symptoms and is sometimes confused with gout. However, it is caused by calcium phosphate, not uric acid. NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases

CDC : 3 Gout is a common form of inflammatory arthritis that is very painful. It usually affects one joint at a time (often the big toe joint). There are times when symptoms get worse, known as flares, and times when there are no symptoms, known as remission. Repeated bouts of gout can lead to gouty arthritis, a worsening form of arthritis. There is no cure for gout, but you can effectively treat and manage the condition with medication and self-management strategies.

KEGG : 37
Gout is a kind of arthritis associated with hyperuricemia. It is triggered due to precipitation and deposition of inflammatory monosodium urate crystals in synovial and other tissues, accompanied by severe pain. The most common symptom include swelling, tenderness, warmth and redness. Mostly, the joint at the base of the big toe is affected, gout progresses with more frequent attacks that involve multiple joints. Joint pain that used to resolve in a week to 10 days could become a milder, but constant pain. Eventually, untreated gout can cause other comorbidities such as high blood pressure, diabetes, chronic kidney disease and cardiovascular disease. The incidence of the disease is more common in 40s men than women, but gout in women after menopause appears increased risk. Recently, the onset in 20s increases. The development of gout is not only associated with sex, age, race and genetics, but also diet and lifestyle are contributed to increasing prevalence of the disease. Epidemiology studies reported that the excessive intake of alcohol and purine rich food, which excessively produce uric acid, leads to accumulation of uric acid.

PubMed Health : 63 About gout: Gout is a metabolic disorder which causes inflammation of the joints. During acute episodes, certain joints swell up within just a few hours and become very sensitive to pain. The inflammation is triggered by tiny needle-shaped crystals of uric acid that mainly build up in the joints. These crystals may form if there is too much uric acid in the body. The inflammation normally goes away on its own within one to two weeks. The pain can be relieved with medication. Most people with gout experience acute attacks every now and then. Months or even years can pass between attacks, but they may be more frequent too. There are a number of options to prevent them. Some people already notice an improvement if they avoid certain foods and other possible triggers. Others may take medication to lower their uric acid levels over the long term. The medication is mostly considered for people who have frequent gout attacks or complications such as kidney stones or lumps called tophi. Many people have high levels of uric acid without it causing any noticeable problems. It's not clear whether this affects their health. It doesn't need to be treated.

Wikipedia : 75 Gout is a form of inflammatory arthritis characterized by recurrent attacks of a red, tender, hot, and... more...

Related Diseases for Gout

Diseases related to Gout via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 580)
# Related Disease Score Top Affiliating Genes
1 phosphoribosylpyrophosphate synthetase superactivity 34.1 PRPS1 HPRT1
2 hyperuricemic nephropathy, familial juvenile, 1 33.9 UMOD SLC22A12 HPRT1
3 kelley-seegmiller syndrome 33.3 HPRT1 APRT
4 lesch-nyhan syndrome 32.1 XDH HPRT1 APRT ADSL
5 hyperuricemia 30.7 XDH UMOD SLC2A9 SLC22A12 SLC17A3 SLC17A1
6 nephrolithiasis, uric acid 30.6 XDH HPRT1
7 nephrolithiasis, calcium oxalate 30.4 XDH UMOD APRT
8 hypouricemia, renal, 1 30.3 SLC2A9 SLC22A12 HPRT1
9 hereditary xanthinuria 29.9 XDH APRT
10 adenine phosphoribosyltransferase deficiency 29.8 XDH HPRT1 APRT
11 xanthinuria, type i 29.4 XDH UMOD APRT
12 xanthinuria 28.5 XDH SLC2A9 SLC22A12 HPRT1 APRT ADSL
13 uric acid concentration, serum, quantitative trait locus 1 12.1
14 autosomal dominant tubulointerstitial kidney disease due to umod mutations 11.9
15 chondrocalcinosis 2 11.8
16 uric acid concentration, serum, quantitative trait locus 4 11.6
17 arthritis 11.6
18 autosomal dominant tubulointerstitial kidney disease, umod-related 11.5
19 crystal arthropathies 11.5
20 autosomal dominant tubulointerstitial kidney disease 11.5
21 polycythemia vera 11.5
22 glycogen storage disease ia 11.4
23 medullary cystic kidney disease 1 11.4
24 ren-related kidney disease 11.3
25 medullary cystic kidney disease 2 11.2
26 nephronophthisis-like nephropathy 1 11.1
27 autosomal dominant tubulointerstitial kidney disease due to ren mutations 11.1
28 occipital neuralgia 11.1
29 rheumatic disease 10.8
30 enthesopathy 10.8
31 arthropathy 10.7
32 chondrocalcinosis 10.6
33 chronic kidney disease 10.6
34 kidney disease 10.6
35 rheumatoid arthritis 10.6
36 urate oxidase, pseudogene 10.5
37 septic arthritis 10.5
38 synovitis 10.5
39 osteoarthritis 10.5
40 diabetes mellitus 10.4
41 back pain 10.4
42 carpal tunnel syndrome 10.4
43 hypertriglyceridemia, familial 10.4
44 systemic lupus erythematosus 10.3
45 vascular disease 10.3
46 lipid metabolism disorder 10.3
47 inflammatory spondylopathy 10.3
48 spondylitis 10.3
49 lupus erythematosus 10.3
50 coronary heart disease 1 10.3

Comorbidity relations with Gout via Phenotypic Disease Network (PDN): (show all 24)


Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Aortic Valve Disease 1
Benign Essential Hypertension Bladder Neck Obstruction
Bronchitis Deficiency Anemia
Familial Atrial Fibrillation First-Degree Atrioventricular Block
Generalized Atherosclerosis Heart Disease
Hypertension, Essential Hypothyroidism
Intermediate Coronary Syndrome Iron Deficiency Anemia
Kidney Disease Mitral Valve Disease
Osteoarthritis Peripheral Vascular Disease
Prostate Cancer Prostatic Hypertrophy
Sinoatrial Node Disease Transient Cerebral Ischemia

Graphical network of the top 20 diseases related to Gout:



Diseases related to Gout

Symptoms & Phenotypes for Gout

UMLS symptoms related to Gout:


back pain, sciatica, muscle cramp

GenomeRNAi Phenotypes related to Gout according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 9.92 ABCG2 ADSL ALDH2 ALPK1 APRT CARMIL1

MGI Mouse Phenotypes related to Gout:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.9 ABCG2 ALDH2 APRT HPRT1 IL1B NLRP3
2 immune system MP:0005387 9.65 ABCG2 ALDH2 APRT HPRT1 IL1B NLRP3
3 renal/urinary system MP:0005367 9.28 ABCG2 ALDH2 APRT HPRT1 NLRP3 SLC22A12

Drugs & Therapeutics for Gout

PubMed Health treatment related to Gout: 63

The treatment of gout has two aims: In the short term, it should provide pain relief during gout attacks.In the long term, it should prevent further attacks and lower the risk of chronic inflammations and joint damage. Gout attacks are treated with anti-inflammatory medications. These include anti-inflammatory painkillers, such as ibuprofen, indometacine or naproxen,steroid medicines (usually tablets with prednisolone), as well asthe gout medicine colchicine. Because colchicine is slow to start working and has certain possible side effects, it is no longer used very often. If a single drug can’t provide enough pain relief, the treatments can be combined. Cooling the affected joint probably also helps, and most people find it very soothing. The goal of long-term gout treatment is to prevent gout attacks and complications by lowering the level of uric acid. This can be done in two ways: Changing your diet: Especially eating less meat, fish and seafood, and drinking less alcohol.Taking medication to lower your uric acid levels, typically allopurinol. Not everyone who has gout needs to take medicine to lower their uric acid levels. In particular, people who have already had a gout attack usually don’t need to take it. This is because some people don't have any problems after that for years, and others only have them rarely. Medication is mainly used if the attacks become more frequent or are very distressing. It also makes sense to take it if complications such as tophi or kidney stones have already developed, or if the functioning of the kidney is affected. Medication might also be an option if changes to your diet aren’t enough to make a difference.

Drugs for Gout (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 298)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
2
Lumiracoxib Approved, Investigational Phase 4 220991-20-8 151166
3
Indomethacin Approved, Investigational Phase 4 53-86-1 3715
4
Febuxostat Approved Phase 4 144060-53-7 134018
5
Etoricoxib Approved, Investigational Phase 4 202409-33-4 123619
6
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
7
Naproxen Approved, Vet_approved Phase 4 22204-53-1 1302 156391
8
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
9
Olmesartan Approved, Investigational Phase 4 144689-63-4, 144689-24-7 130881 158781
10
Lithium carbonate Approved Phase 4 554-13-2
11
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
12
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
13
Nitric Oxide Approved Phase 4 10102-43-9 145068
14
Nitroglycerin Approved, Investigational Phase 4 55-63-0 4510
15
Amlodipine Approved Phase 4 88150-42-9 2162
16
Angiotensin II Approved, Investigational Phase 4 11128-99-7, 68521-88-0, 4474-91-3 172198
17
Losartan Approved Phase 4 114798-26-4 3961
18
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
19
Benazepril Approved, Investigational Phase 4 86541-75-5 5362124
20
Sotalol Approved Phase 4 959-24-0, 3930-20-9 5253
21
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
22
Histamine Approved, Investigational Phase 4 51-45-6 774
23
Etanercept Approved, Investigational Phase 4 185243-69-0
24
Fexofenadine Approved, Investigational Phase 4 83799-24-0 3348
25
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
26
Allopurinol Approved Phase 4 315-30-0 2094
27
Lesinurad Approved, Investigational Phase 4 878672-00-5 53465279
28
Probenecid Approved, Investigational Phase 4 57-66-9 4911
29
Phenytoin Approved, Vet_approved Phase 4 57-41-0 1775
30
Inulin Approved, Investigational, Nutraceutical Phase 4 9005-80-5 24763
31
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
32
Uric acid Investigational Phase 4 69-93-2 1175
33 Tocolytic Agents Phase 4
34 Cyclooxygenase 2 Inhibitors Phase 4
35 Cyclooxygenase Inhibitors Phase 4
36 Neuromuscular Agents Phase 4
37 abobotulinumtoxinA Phase 4
38 Cholinergic Agents Phase 4
39 Acetylcholine Release Inhibitors Phase 4
40 Botulinum Toxins Phase 4
41 Botulinum Toxins, Type A Phase 4
42 Diacetylrhein Phase 4
43 Antacids Phase 4
44 Proton Pump Inhibitors Phase 4
45 Anti-Ulcer Agents Phase 4
46
Olmesartan medoxomil Phase 4 144689-63-4 130881
47 Antipsychotic Agents Phase 4
48 HIV Protease Inhibitors Phase 4
49 Hormones Phase 4
50
protease inhibitors Phase 4

Interventional clinical trials:

(show top 50) (show all 301)
# Name Status NCT ID Phase Drugs
1 Efficacy and Safety of the Non-Steroidal Anti-Inflammatory Drug Etoricoxib in the Treatment of Acute Ankle Sprain in Sports: A Randomized Double-Blind Comparative Study Among 2 Treatments in the Acute Phase Unknown status NCT00525993 Phase 4 etoricoxib 90mg 14 days;etoricoxib 60mg daily for 14 days
2 A 1-Week, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active-Controlled, Parallel Trial Comparing Lumiracoxib (400 mg Once Daily) in Patients With Acute Flares of Gout, Using Indomethacin (50 mg Three Times a Day) Completed NCT00170781 Phase 4 Lumiracoxib
3 Efficacy and Safety of Colchicine for the Prevention of Gout Flares During the Initiation of Allopurinol Completed NCT01451645 Phase 4 Colchicine (Colcrys®);placebo;allopurinol
4 A Randomized, Double-Blind, Active-Comparator-Controlled 5-Day Trial of the Effect of Etoricoxib 120 mg Versus Indomethacin 150 mg in the Treatment of Acute Gout Completed NCT00142558 Phase 4 MK0663; etoricoxib / Duration of Treatment: 5 Days;Comparator: indomethacin 75 mg sustained release capsule / Duration of Treatment: 5 Days
5 Does Allopurinol Prolong a Treated, Acute Gout Flare? Completed NCT01988402 Phase 4 allopurinol;Placebo (sugar pill)
6 Therapeutic Effect of Botulinum Toxin Type A in Addition to Total Contact Insole in Treating Painful Hallux valgus-a Pilot Study Completed NCT01501500 Phase 4 BOTOX;Normal Saline (0.9% NaCl)
7 Long-term Allopurinol Safety Study Evaluating Outcomes in Gout Patients (LASSO) Completed NCT01391325 Phase 4 Allopurinol
8 Shifting the Paradigm of Gout: An Assessment of Chronic Synovial-Based Inflammation and Its Role With Serum Urate Levels. Completed NCT01112982 Phase 4 Febuxostat;Colchicine
9 Therapy for Acute Gout: Does Initial Use of Allopurinol Effect Duration and/or Recurrence Rate of Acute Attacks Completed NCT01310673 Phase 4 Allopurinol;Placebo
10 Diacerein Combined With Febuxostat Relieves Symptoms of Gout by Suppressing IL-1βinflammation Completed NCT02060552 Phase 4 Diacerein;Colchicine;Febuxostat
11 Multi-centre, Open-label, Active-comparator, Pragmatic Clinical Trial of Low-dose Colchicine Versus Naproxen in Patients With Acute Gout. Completed NCT01994226 Phase 4 Low-dose colchicine;Naproxen 750 mg/250 mg
12 A Prospective, Non-comparative, Single Centre Study to Determine the Performance & Survivorship of the SIGMA HP® PARTIAL KNEE SYSTEM. Completed NCT01529099 Phase 4
13 Optimal Administration of Allopurinol in Dialysis Patients : A Chronotherapy Trial Completed NCT02477488 Phase 4 Allopurinol
14 Treatment of Uric Acid With the Xanthine Oxidase Inhibitor Febuxostat: Effects on Blood Pressure, Metabolic Markers, and Aortic Stiffness in Prehypertensive Completed NCT01472692 Phase 4 Febuxostat
15 Febuxostat (Zurig) Efficacy & Safety Trial in Comparison With Allopurinol in Hyperuricemic Subjects With or Without Gout Completed NCT02600780 Phase 4 Febuxostat;Allopurinol
16 Do Xanthine Oxidase Inhibitors Reduce Both Left Ventricular Hypertrophy and Endothelial Dysfunction in Cardiovascular Patients With Renal Dysfunction? Completed NCT00688480 Phase 4 Placebo;Allopurinol
17 The Effect of Intensive Urate Lowering Therapy (ULT) With Febuxostat in Comparison With Allopurinol on Cardiovascular Risk in Patients With Gout Using Surrogate Markers: a Randomized, Controlled Trial Completed NCT02500641 Phase 4 Febuxostat 80/120mg/day;Allopurinol 100 up to 600mg/day;Colchicine;Naproxen;Omeprazole
18 A Double Blind Cross-over Study of the Efficacy of a Proprietary Cherry Juice Blend in Osteoarthritis of the Knee. Completed NCT00443092 Phase 4
19 Effects of Pharmacological Reversal of Hyperuricemia on Features of the Metabolic Syndrome Completed NCT01654276 Phase 4 Febuxostat
20 Effect of Probenecid on Pharmacokinetics, and Tolerability of Olmesartan in Healthy Chinese Volunteers Completed NCT01907373 Phase 4 olmesartan medoxomil;olmesartan medoxomil+probenecid
21 A Double-Blind, Placebo Controlled Augmentation Study With Allopurinol for Treatment Resistant Mania Completed NCT00643123 Phase 4 Allopurinol
22 A Deep Phenotyping Approach to Assess the Effect of Uric Acid Lowering in Patients With Uncomplicated Type 1 Diabetes Mellitus Completed NCT02344602 Phase 4 Febuxostat
23 Does Allopurinol Regress Left Ventricular Hypertrophy in Patients With Treated Essential Hypertension? Completed NCT02237339 Phase 4 Allopurinol;Placebo
24 Febuxostat, Blood Pressure and the Intrarenal Renin-Angiotensin System (RAS) Completed NCT01328769 Phase 4 Febuxostat;Placebo
25 Does ALlopurinol Regress lefT Ventricular Hypertrophy in End Stage REnal Disease: The ALTERED Study Completed NCT01951404 Phase 4 Allopurinol;Placebo (for allopurinol)
26 A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients With Uncontrolled GOut Receiving KRYSTEXXA® (Pegloticase) (MIRROR Randomized Controlled Trial [RCT]) Recruiting NCT03994731 Phase 4
27 Xanthine Oxidase Inhibition for Improvement of Long-term Outcomes Following Ischaemic Stroke and Transient Ischaemic Attack Recruiting NCT02122718 Phase 4 Allopurinol;Placebo
28 Efficacy and Safety of a Single-pill Fixed Combination of Sufficient Losartan/Hydrochlorothiazide in Chinese Hypertensive Patients (FOCUS) Recruiting NCT03946514 Phase 4 losartan/hydrochlorothiazide;amlodipine/hydrochlorothiazide
29 ACEI/CCB Versus ACEI/DIU Combination Antihypertensive Therapy in Chinese Hypertensive Patients (ACvAD) Recruiting NCT03682692 Phase 4 ACEI/CCB;ACEI/DIU
30 A Pilot and Feasibility Study to Determine if a Common Atrial Fibrillation Risk Locus Modulates Differential Response to Antiarrhythmic Drugs Recruiting NCT02347111 Phase 4 Flecainide;Sotalol
31 A Multicenter, Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients With Uncontrolled GOut Receiving KRYSTEXXA® (Pegloticase) (MIRROR Open-Label [OL]) Active, not recruiting NCT03635957 Phase 4
32 CSP #594 - Comparative Effectiveness in Gout: Allopurinol vs. Febuxostat Active, not recruiting NCT02579096 Phase 4 Allopurinol;Febuxostat;Placebo, vehicle control (Febuxostat-shaped);Placebo, vehicle control (Allopurinol-shaped)
33 The Effects of BCRP Q141K on Allopurinol Pharmacokinetics and Dynamics Active, not recruiting NCT02956278 Phase 4 Allopurinol
34 TRPV2 Agonists in Fontan Circulation Patients Active, not recruiting NCT03965351 Phase 4 Probenecid
35 Anti-inflammatory Effects of Colchicine in Patients Undergoing Percutaneous Coronary Intervention Active, not recruiting NCT01709981 Phase 4 Colchicine;Placebo
36 The Impact of Urate-lowering Therapy on Kidney Function in Patients With/Without Gout Enrolling by invitation NCT03336203 Phase 4 Febuxostat 80 MG Oral Tablet or Allopurinol 300 MG Oral Tablet
37 Investigator-Initiated, Pilot Study Evaluating The Efficacy Of Etanercept In Acute Gout Not yet recruiting NCT03636373 Phase 4 Etanercept;Triamcinolone Acetonide
38 Comparison of Maximum Blood Concentrations of Colchicine Between Responders and Non-responders to Colchicine Treatment During Gout Flare Not yet recruiting NCT03933007 Phase 4 Colchicine,;midazolam,;fexofenadine
39 A Single-center, Prospective, Randomized, Double-blind, Controlled Trial for the Effect of Allopurinol Sustained-release Capsules on the Stability of Coronary Plaques in Patients With Acute Coronary Syndrome Not yet recruiting NCT03745729 Phase 4 allopurinol sustained-release capsules;placebo capsules
40 A Phase 4, Study to Evaluate the Safety and Efficacy of Lesinurad 200 mg in Combination With a Xanthine Oxidase Inhibitor (XOI), Compared With an XOI Alone, in Subjects With Gout and Estimated Creatinine Clearance (eCrCl) 30 to <60 mL/Min Who Have Not Achieved Target Serum Uric Acid Levels (sUA) on an XOI Alone Terminated NCT03226899 Phase 4 Lesinurad;XOI;Placebo
41 Allopurinol as a Possible New Therapy for Acute Coronary Syndromes:The Next Steps Terminated NCT01457820 Phase 4 Allopurinol;Allopurinol;Placebo
42 Evaluating Transporter Protein Inhibitors in Patients With Epilepsy Terminated NCT00610532 Phase 4 phenytoin;phenytoin and probenecid
43 Mechanistic Effects of Colchicine in Patients With Myocardial Infarction A Single Center Phase 4 Single Arm Open-label Study Evaluating the FDA-approved Drug, Colchicine, at the FDA-approved Gout Dose in Patients With Myocardial Infarction Withdrawn NCT02995512 Phase 4 Colchicine 0.6 mg tablets
44 A Clinical Trial About the Efficacy and Safety of HuZhen Capsule in Treating Patients With Acute Gout: A 72 Hours, Multi-center, Randomized, Double-blind, Parallel Placebo Compared Clinical Trial Unknown status NCT02674776 Phase 3 HuZhen Capsule;Placebo Capsule
45 A Feasibility Study to Undertake a Definitive Randomised Multi-centre, Double-blind, Double-dummy Controlled Study of a Novel Agent Anakinra vs. Depo-Medrone for Acute Gout Attacks in Patients With Moderate Chronic Kidney Disease Unknown status NCT02578394 Phase 2, Phase 3 Anakinra 100mg and Placebo Depo-Medrone;Depo-Medrone 120mg and Placebo (Anakinra)
46 The Effects of Doxazosin and Nifedipine on Blood Pressure Variability and Uric Acid in Plasma in Hypertensive Patients Unknown status NCT02563405 Phase 2, Phase 3 Doxazosin;Nifedipine
47 A 36-week Open-label Extension Study of CACZ885H2361 on the Safety and Tolerability of Canakinumab 150 mg s.c. Pre-filled Syringe (PFS) in Treating Acute Gouty Arthritis Flares in Frequently Flaring Patients Completed NCT01431638 Phase 3 Canakinumab 150mg in prefilled syringe
48 A Randomized, Double-blind, Active-controlled Study of Canakinumab Prefilled Syringes or Reconstituted Lyophilizate Versus Triamcinolone Acetonide for Treating Acute Gouty Arthritis Flares in Frequently Flaring Patients Completed NCT01356602 Phase 3 Canakinumab pre-filled syringe;Canakinumab lyophilized powder;Triamcinolone Acetonide;Placebo
49 An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective Completed NCT01470989 Phase 3 ACZ885
50 A Phase 3, Randomized, Double-Blind, Multicenter, Active-Controlled Trial To Evaluate The Efficacy And Safety Of Celecoxib (Celebrex®) And Indomethacin In The Treatment Of Moderate To Severe Acute Gouty Arthritis Completed NCT00549549 Phase 3 Indomethacin;Celecoxib;Celecoxib;Celecoxib

Search NIH Clinical Center for Gout

Inferred drug relations via UMLS 72 / NDF-RT 51 :


ACETYLSALICYLATE SODIUM
Allopurinol
Aspirin
ASPIRIN PWDR
Betamethasone
Bupivacaine
Colchicine
Colchicine
Corticotropin
Cortisone acetate
Dexamethasone
Diclofenac
Gout Suppressants
Hydrocortisone
Ibuprofen
Ibuprofen
Indomethacin
Indomethacin
INDOMETHACIN PWDR
INDOMETHACIN SODIUM
Meclofenamic acid
Methylprednisolone
Naproxen
Naproxen
Naproxen sodium
Prednisolone
Prednisone
Probenecid
solufenum
Sulfinpyrazone
Sulindac
Sulindac
Tetracosactide
Triamcinolone

Cochrane evidence based reviews: gout

Genetic Tests for Gout

Anatomical Context for Gout

MalaCards organs/tissues related to Gout:

41
Kidney, Heart, Bone, Liver, Skin, Testes, Neutrophil

The Foundational Model of Anatomy Ontology organs/tissues related to Gout:

19
Joint

Publications for Gout

Articles related to Gout:

(show top 50) (show all 12310)
# Title Authors PMID Year
1
Percutaneous endoscopic treatment for cervical ligamentum flavum gouty tophus: A case report. 38 17
31096496 2019
2
Diagnostic challenges of spinal gout: A case series. 38 17
31008969 2019
3
Disseminated subcutaneous nodules and destructive polyarthritis. 17
30996027 2019
4
Childhood course of renal insufficiency in a family with a uromodulin gene mutation. 9 38
20151160 2010
5
Four generations of transition-state analogues for human purine nucleoside phosphorylase. 9 38
20212140 2010
6
Refractory polyarticular gouty arthritis as a manifestation of immune reconstitution inflammatory syndrome. 9 38
20051757 2010
7
The NLRP3 inflammasome: a sensor for metabolic danger? 9 38
20075245 2010
8
Allopurinol, xanthine oxidase, and cardiac ischemia. 9 38
19794315 2009
9
Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout. 9 38
20109996 2009
10
The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study. 9 38
19635719 2009
11
In vitro xanthine oxidase inhibitory activity of the fractions of Erythrina stricta Roxb. 9 38
19467311 2009
12
Severe gouty arthritis and mild neurologic symptoms due to F199C, a newly identified variant of the hypoxanthine guanine phosphoribosyltransferase. 9 38
19565499 2009
13
Febuxostat (Uloric) for chronic treatment of gout. 9 38
19448587 2009
14
Adenine phosphoribosyltransferase deficiency in a Chinese man with early-onset gout. 9 38
19435978 2009
15
Crystal ball gazing: new therapeutic targets for hyperuricaemia and gout. 9 38
19109320 2009
16
Role of urate, xanthine oxidase and the effects of allopurinol in vascular oxidative stress. 9 38
19436671 2009
17
Familial juvenile hyperuricemic nephropathy: report on a new mutation and a pregnancy. 9 38
19203555 2009
18
The effect of age and gender on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase. 9 38
18635756 2008
19
Abnormal expression and processing of uromodulin in Fabry disease reflects tubular cell storage alteration and is reversible by enzyme replacement therapy. 9 38
18651238 2008
20
Normal HPRT coding region in complete and partial HPRT deficiency. 9 38
18316217 2008
21
[Inhibitors of xanthine oxidoreductase]. 9 38
18409526 2008
22
Synthesis of N-aryl-5-amino-4-cyanopyrazole derivatives as potent xanthine oxidase inhibitors. 9 38
17692432 2008
23
[New antihyperuricemic medicine: febuxostat, Puricase, etc]. 9 38
18409528 2008
24
The potential role for xanthine oxidase inhibition in major intra-abdominal surgery. 9 38
18074171 2008
25
Febuxostat. 9 38
18729537 2008
26
The spectrum of autoinflammatory diseases: recent bench to bedside observations. 9 38
18281860 2008
27
Xanthine oxidase inhibitors the unappreciated treatment for heart failure. 9 38
18220728 2007
28
Arts syndrome is caused by loss-of-function mutations in PRPS1. 9 38
17701896 2007
29
HPRT deficiency in a two-month-old child presenting acute renal failure and gout with a new deletion of two bases in exon 3 of the HPRT gene. 9 38
17416296 2007
30
Identification of a new single-nucleotide mutation on the hypoxanthine-guanine phosphoribosyltransferase gene from 983 cases with gout in Taiwan. 9 38
17309125 2007
31
Genetics and experimental models of crystal-induced arthritis. Lessons learned from mice and men: is it crystal clear? 9 38
17278928 2007
32
Febuxostat: a novel non-purine selective inhibitor of xanthine oxidase for the treatment of hyperuricemia in gout. 9 38
19075968 2007
33
Febuxostat: a selective xanthine oxidase inhibitor for the treatment of hyperuricemia and gout. 9 38
17132810 2006
34
Pathogenesis, clinical findings and management of acute and chronic gout. 9 38
17213786 2006
35
Association between intronic SNP in urate-anion exchanger gene, SLC22A12, and serum uric acid levels in Japanese. 9 38
16920156 2006
36
Metabolic diseases: gout. 9 38
17113968 2006
37
Proteomic analysis of Down's syndrome patients with gout. 9 38
16500633 2006
38
Crystal-induced arthropathies: recent investigative advances. 9 38
16582687 2006
39
Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. 9 38
16507884 2006
40
Partial HPRT deficiency (Kelley-Seegmiller syndrome). 9 38
16649740 2006
41
Mutations in hepatocyte nuclear factor-1beta and their related phenotypes. 9 38
15930087 2006
42
Familial nephropathy associated with hyperuricemia in Spain: our experience with 3 families harbouring a UMOD mutation. 9 38
17065110 2006
43
Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects. 9 38
16884320 2006
44
Efficacy and safety of allopurinol in patients with the Lesch-Nyhan syndrome and partial hypoxanthine- phosphoribosyltransferase deficiency: a follow-up study of 18 Spanish patients. 9 38
17065067 2006
45
HPRTSardinia: a new point mutation causing HPRT deficiency without Lesch-Nyhan disease. 9 38
16216473 2006
46
Febuxostat compared with allopurinol in patients with hyperuricemia and gout. 9 38
16339094 2005
47
Febuxostat (Teijin/Ipsen/TAP). 9 38
16312139 2005
48
Association between cigarette smoking and hypoxanthine guanine phosphoribosyltransferase activity. 9 38
16358551 2005
49
Eighteen-year follow-up of a patient with partial hypoxanthine phosphoribosyltransferase deficiency and a new mutation. 9 38
15965771 2005
50
Febuxostat: a non-purine, selective inhibitor of xanthine oxidase for the management of hyperuricaemia in patients with gout. 9 38
16022578 2005

Variations for Gout

ClinVar genetic disease variations for Gout:

6
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 DARS2 NM_018122.5(DARS2): c.492+2T> C single nucleotide variant Pathogenic rs142433332 1:173800770-173800770 1:173831632-173831632
2 DARS2 NM_018122.5(DARS2): c.228-21_228-20delinsC indel Pathogenic rs1553201258 1:173797450-173797451 1:173828312-173828313

Expression for Gout

Search GEO for disease gene expression data for Gout.

Pathways for Gout

Pathways related to Gout according to KEGG:

37
# Name Kegg Source Accession
1 Purine metabolism hsa00230

GO Terms for Gout

Cellular components related to Gout according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.81 UMOD SLC22A12 SLC22A11 PDZK1 IL1B HPRT1
2 apical plasma membrane GO:0016324 9.17 UMOD SLC2A9 SLC22A12 SLC22A11 SLC17A3 SLC17A1
3 brush border membrane GO:0031526 9.13 SLC22A12 SLC17A3 PDZK1

Biological processes related to Gout according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 transmembrane transport GO:0055085 9.7 SLC2A9 SLC22A12 SLC22A11 SLC17A3 SLC17A1 SLC16A9
2 grooming behavior GO:0007625 9.55 HPRT1 APRT
3 purine-containing compound salvage GO:0043101 9.54 HPRT1 APRT
4 phosphate ion transport GO:0006817 9.52 SLC17A3 SLC17A1
5 organic anion transport GO:0015711 9.51 SLC22A11 SLC17A3
6 nucleoside metabolic process GO:0009116 9.5 PRPS1 HPRT1 APRT
7 sialic acid transport GO:0015739 9.49 SLC17A3 SLC17A1
8 ribonucleoside monophosphate biosynthetic process GO:0009156 9.48 PRPS1 ADSL
9 purine ribonucleoside salvage GO:0006166 9.46 HPRT1 APRT
10 interleukin-1 beta production GO:0032611 9.43 NLRP3 IL1B
11 purine nucleotide biosynthetic process GO:0006164 9.43 PRPS1 HPRT1 ADSL
12 adenine salvage GO:0006168 9.4 HPRT1 APRT
13 adenine metabolic process GO:0046083 9.37 HPRT1 APRT
14 urate transport GO:0015747 9.26 SLC2A9 SLC22A12 SLC17A3 SLC17A1
15 urate metabolic process GO:0046415 9.23 SLC2A9 SLC22A12 SLC22A11 SLC17A3 SLC17A1 SLC16A9

Molecular functions related to Gout according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transmembrane transporter activity GO:0022857 9.5 SLC2A9 SLC22A12 SLC22A11
2 symporter activity GO:0015293 9.43 SLC17A3 SLC17A1 SLC16A9
3 organic anion transmembrane transporter activity GO:0008514 9.16 SLC22A11 SLC17A3
4 sialic acid transmembrane transporter activity GO:0015136 8.96 SLC17A3 SLC17A1
5 urate transmembrane transporter activity GO:0015143 8.8 SLC2A9 SLC22A12 SLC17A3

Sources for Gout

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....